UNSPSC 51384515: Oxaprozin

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MHJ80W9LRB, chemically known as 4,5-diphenyl-2-oxazolepropionic acid but generally known as oxaprozin, which bears US NIH Compound Identifier 4614. European Medicines Agency schedules Oxaprozin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09502MIG.

UNSPSC 51384515 Oxaprozin, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The source contains three opportunities: a Seminole County, Florida IFB for naloxone and drug deactivation systems; a Texas HHS Commission RFI on direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and over-the-counter products. None of these solicitations involve oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID), or address procurement of that specific pharmaceutical commodity. The recent opportunities instead cover naloxone (an opioid antagonist), broad generic pharmaceutical supply agreements through wholesalers, and exploration of direct pharmacy contracting models. This mismatch suggests the code shows little relevant recent activity for oxaprozin specifically, and the tagged opportunities do not reflect the actual scope of the Commodity code as named.

The issuing bodies in the recent activity span county health departments (Seminole County), state health agencies (Texas HHS Commission), and cooperative purchasing vehicles serving multiple state and local jurisdictions (MMCAP, which includes Minnesota and Oregon participation). Geographic activity touches Florida, Texas, Minnesota, and Oregon. Because the source contains no recent solicitations actually seeking oxaprozin procurement, no representative opportunities for the code itself can be named.